Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD - Free Report) in a report published on Monday,Benzinga reports.

A number of other research firms also recently weighed in on FOLD. Cantor Fitzgerald increased their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Morgan Stanley restated an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Finally, Guggenheim lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.88.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.21 during midday trading on Monday, reaching $9.23. 3,587,088 shares of the stock were exchanged, compared to its average volume of 2,418,727. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The stock has a market capitalization of $2.76 billion, a PE ratio of -27.15 and a beta of 0.62. Amicus Therapeutics has a 52 week low of $8.78 and a 52 week high of $14.03. The company has a fifty day moving average price of $9.86 and a 200 day moving average price of $10.54.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 22,901 shares of company stock worth $259,863 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Amicus Therapeutics

Hedge funds have recently bought and sold shares of the business. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics during the third quarter worth about $26,000. Hazlett Burt & Watson Inc. increased its holdings in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 1,569 shares during the period. Blue Trust Inc. raised its position in shares of Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.